These findings emphasize the role of metabolic health in influencing the course and severity of PsA. The authors emphasize ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in ...

Like most first-time fathers, Mr John Dzido was excited when his son Caleb was born in 2008. He was also happy that his first ...

APEX shows Tremfya is the first IL-23 inhibitor to slow joint damage in psoriatic arthritis, offering early, multi-domain ...

Sickle cell disease affects thousands of Indian children, yet its most dangerous complications often go unnoticed. Experts ...

Sickle Cell disease disproportionately affects India’s tribal populations, with complications impacting both children and ...

AS Guyana observes World Sickle Cell Day today, medical professionals are urging that there be staunch support for those affected by the disease.

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

Early diagnosis of sickle cell disease (SCD) in infants is crucial. Learn how to recognize early signs like hand-foot syndrome, and why newborn screening is vital for reducing complications and ...